Intellia and ONK collaborate on cancer candidates
Endpoints News – View full story
Intellia-ONK ink up to $920 million pact for 5 CRISPR-edited cancer cell therapies
Fierce Biotech – View full story
Intellia and ONK Therapeutics enter collaboration
The Pharma Letter – View full story
Intellia follows CRISPR peers with deal to explore ‘natural killer’ cell therapy
BioPharma Dive – View full story
Cancer killer cell group has two shots at success
The Irish Times – View full story
ONK closes $21.5 million series A for cord blood-derived NK cell therapy
BioWorld – View full story (behind paywall)
Galway cancer killer cell group ONK raises €19 million
The Irish Times – View full story
